Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| NAMI-A | ?98% ruthenium (Ru) basis (elemental analysis). Group: Fluorescence/luminescence spectroscopy. |  |
| NAMI-A | NAMI-A is a ruthenium anticancer agent and a metastasis inhibitor. NAMI is an acronym for "New Anti-tumour Metastasis Inhibitor", while the -A suffix indicates that this is the first of a potential series. NAMI-A is a potent agent for the treatment of solid tumor metastases as well as when these tumor lesions are in an advanced stage of growth. NAMI-A is endowed with a mechanism of action unrelated to direct tumor cell cytotoxicity, and such mechanism of action is responsible for a reduced host toxicity. Synonyms: ImH[trans-RuCl4(DMSO)Im]; Na[trans-RuCl(4)(DMSO)Im; Imidazolium trans-imidazoledimethyl sulfoxide-tetrachlororuthenat; Imidazolium-bis (imidazole) di methyl sulfoxideimidazotetrachlororuthenate (III) ; Imidazolium-bis (imidazole) di methyl sulfoxideimidazotetrachlororuthenate (III). Grades: >98%. CAS No. 201653-76-1. Molecular formula: C8H15Cl4N4ORuS. Mole weight: 458.18. |  |
| NAMI-A | NAMI-A is a ruthenium-based agent characterized by selective activity against tumor metastasis, inhibiting adhesion and migration. Uses: Scientific research. Group: Signaling pathways. CAS No. 201653-76-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-19376. |  |
| KP1019 | KP1019, also known as FFC14A, is just the second ruthenium-based anticancer agent after NAMI-A which was developed to the stage of clinical trials. Important steps in the mode of action of KP1019 are thought to be the binding to the serum protein transferrin and the transport into the cell via the transferrin pathway. Additionally, the selective activation by reduction in the tumor might contribute to the low side effects observed in in vivo studies. Apoptosis is induced at non-toxic levels via the mitochondrial pathway. These features distinguish it from the established platinum anticancer drugs and suggest that different types of cancer might be treatable with this drug. Indeed, promising activity against certain types of tumors, which are not successfully treatable with cisplatin, and only a very low incidence of acquired resistance has been observed in in vitro and in vivo studies. Recently, a clinical phase I trial was finished in which none of the treated patients experienced serious side effects, while disease stabilization in five of six evaluable patients was achieved. Synonyms: KP1019; KP 1019; KP-1019; FFC14A; indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]. CAS No. 124875-20-3. Molecular formula: C21H19Cl4N6Ru. Mole weight: 598.30. | |
Our database is helping our users find suppliers everyday.
